Pub. Date : 2017
PMID : 28542373
2 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | The relative risks of all-cause mortality with SGLT2 inhibitor use were 0.68 (95% credible interval: 0.57-0.80), 0.74 (0.49-1.10), 0.63 (0.46-0.87), 0.71 (0.55-0.90), and 0.65 (0.54-0.78), compared with placebo, metformin, sulfonylurea, TZD, and DPP4 inhibitor, respectively. | Metformin | solute carrier family 5 member 2 | Homo sapiens |
| 2 | The relative risks of cardiovascular-related mortality with SGLT2 inhibitor use were 0.61 (0.50-0.76), 0.81(0.36-1.90), 0.52(0.31-0.88), 0.66(0.49-0.91), and 0.61(0.48-0.77), compared with placebo, metformin, sulfonylurea, TZD, and DPP4 inhibitor, respectively. | Metformin | solute carrier family 5 member 2 | Homo sapiens |